Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Triple-negative breast cancer (TNBC) is aggressive, lacks targeted therapies, and often metastasizes.
• Current treatments, including immune checkpoint inhibitors, have limited efficacy due to tumor microenvironment challenges.
• Messenger RNA (mRNA) immunotherapies represent a novel approach for personalized cancer treatment.

Purpose of the Study:

• To review the emerging strategies of mRNA-based immunotherapies in triple-negative breast cancer (TNBC).
• To highlight the role of nanotechnology in advancing mRNA delivery for TNBC treatment.
• To discuss the future potential of integrating antigen targeting, immune cell engineering, and delivery technologies for TNBC.

Main Methods:

• Review of current literature on mRNA-based immunotherapies for TNBC.
• Analysis of three principal mRNA strategies: personalized vaccines, mRNA-engineered immune cells, and mRNA-encoded immunomodulators.
• Examination of the role of nano delivery systems in enhancing mRNA therapy efficacy and safety.

Main Results:

• mRNA platforms are being developed as personalized vaccines, engineered immune cells (CAR-T, TCR-T), and immunomodulators.
• Nano delivery systems are crucial for protecting mRNA, improving cellular uptake, and targeting tumors or lymphoid tissues.
• Ongoing optimization of nanoparticles aims to enhance tissue specificity, mRNA integrity, and reduce toxicity.

Conclusions:

• mRNA-based immunotherapies show significant promise for overcoming therapeutic barriers in TNBC.
• Integration of precision antigen targeting, immune cell engineering, and advanced delivery technologies is key for future progress.
• These approaches offer the potential for more effective and personalized treatment strategies for TNBC patients.